Eli Lilly & Co. (NYSE:LLY) has reportedly finalized a $2.75 billion agreement to introduce AI-developed drugs from Hong Kong’s Insilico Medicine to the global market.
Details Of The Deal
According to a CNBC report, the deal involves an upfront payment of $115 million to Insilico, with additional payments tied to regulatory and commercial achievements, plus royalties on future sales. Insilico has created at least 28 drugs using generative AI, with nearly half already in clinical stages, according to Alex Zhavoronkov, Insilico’s CEO.
The collaboration between the two firms began with an AI-based software licensing deal in 2023. Andrew Adams, Lilly’s group vice president of Molecule Discovery, emphasized the partnership’s potential to explore …
This post was originally published here
